To bring rheumatologists up to date on various recent proposals to restrict reproductive healthcare for women and how that may impact care of their patients, a rheumatologist will join an attorney to review pending laws and their status during a session on Tuesday.
“A better way to think about immunodeficiency is as immune dysregulation. It is paradoxical, but many patients with immunodeficiencies are also at increased risk for autoimmunity and for granuloma formation,”” said Mahta Mortezavi, MD.
New technologies make it possible to measure tens of thousands of cells at once, giving researchers an opportunity for improving our understanding of disease on a molecular level.
A Monday afternoon Clinical Practice session will examine several comorbidities that can complicate management and affect longterm prognoses for patients.
“There is a great need to recognize when to treat this disease, because, as with many of our other rheumatic diseases, there’s a window of opportunity,” said Suzanne Li, MD, PhD.
Recent and ongoing research continues to increase understanding of the underlying mechanisms of myositis, providing important groundwork for the development of new diagnostic and screening tools and novel
Jinoos Yazdany, MD, MPH, updated attendees about the latest from the ACR’s RISE registry, which aims to capitalize on electronic health record data to improve patient care. She said that the data collected and analyzed thus far has provided benefits.
Clinicians are often faced with uncertainty regarding the diagnosis and treatment of patients with non-radiographic axial spondyloarthritis (SpA), but the Monday Clinical Practice session Axial SpA or No Axial SpA: What To Do When X-Rays Are Negative will help to shed light on these important…
“For many years after it was first described in the 1930s, Sjögren’s was considered to be extremely rare and was actually listed in the registry of the National Organization of Rare Diseases,” said Frederick Vivino, MD, MS, FACR. “In recent years, however, the pendulum regarding…
Methotrexate has long been the most common and most effective first-line therapy for the treatment of RA, and new and ongoing research continues to shed new light on optimal timing and dosing.